1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. BeiGene, Ltd.
  6. News
  7. Summary
    BGNE   US07725L1026

BEIGENE, LTD.

(BGNE)
  Report
Delayed Nasdaq  -  05/17 01:09:41 pm EDT
138.49 USD   +7.21%
03:08aBeiGene to Open Regional Office in Switzerland
MT
01:01aBeiGene Strengthens European Presence With the Opening of Regional Office in Basel, Switzerland
BU
01:00aBeiGene, Ltd. Announces the Opening of a New Regional Office in Basel, Switzerland
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

BeiGene Says China's Medical Products Regulator Accepts Supplemental NDA for Blood Cell Cancer Drug

01/20/2022 | 05:52am EDT


ę MT Newswires 2022
All news about BEIGENE, LTD.
03:08aBeiGene to Open Regional Office in Switzerland
MT
01:01aBeiGene Strengthens European Presence With the Opening of Regional Office in Basel, Swi..
BU
01:00aBeiGene, Ltd. Announces the Opening of a New Regional Office in Basel, Switzerland
CI
05/12BeiGene to Demonstrate Strength of Hematology Portfolio and Pipeline at European Hemato..
BU
05/11Asian ADRs Move Higher in Wednesday Trading
MT
05/10Asian ADRs Climb Higher in Tuesday Trading
MT
05/09Morgan Stanley Lowers BeiGene's Price Target to $300 From $338, Maintains Overweight Ra..
MT
05/09INSIDER SELL : BeiGene
MT
05/09BEIGENE, LTD. Management's Discussion and Analysis of Financial Condition and Results ..
AQ
05/05BeiGene Swings to Q1 Net Loss as Revenue Declines
MT
More news
Analyst Recommendations on BEIGENE, LTD.
More recommendations
Financials (USD)
Sales 2022 1 417 M - -
Net income 2022 -1 407 M - -
Net cash 2022 2 945 M - -
P/E ratio 2022 -8,75x
Yield 2022 -
Capitalization 13 328 M 13 328 M -
EV / Sales 2022 7,33x
EV / Sales 2023 5,44x
Nbr of Employees 8 300
Free-Float 99,0%
Chart BEIGENE, LTD.
Duration : Period :
BeiGene, Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BEIGENE, LTD.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 16
Last Close Price 129,18 $
Average target price 312,13 $
Spread / Average Target 142%
EPS Revisions
Managers and Directors
John V. Oyler Director
Xiao Bin Wu President & Chief Operating Officer
Julia Wang Chief Financial & Accounting Officer
Lai Wang Global Head-Research & Development
Christiane Langer Senior Vice President-Global Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
BEIGENE, LTD.-52.32%13 328
GILEAD SCIENCES, INC.-14.28%78 068
REGENERON PHARMACEUTICALS, INC.3.72%70 575
VERTEX PHARMACEUTICALS15.74%65 005
WUXI APPTEC CO., LTD.-16.67%42 275
BIONTECH SE-41.35%36 745